EN
抗体药类似物
Research Grade Lorukafusp Alfa
All
  • CatalogTD-YP115026
  • ClonalitymAb
  • Application Research Grade Biosimilar
  • Synonyms14.18 mAb, 14.18-IL-2, EMD273063, EMD-273063, Hu14.18-IL-2, Hu14.18-IL2, anti-GD2 fused to IL2, hu14.18-IL2, hu14.18-Interleukin-2 fusion protein, CAS: 2131168-99-3
  • 规格
    1mg
  • 价格
    ¥询价
定制服务咨询

Research Grade Lorukafusp Alfa


Catalog No. TD-YP115026
Species reactivity General
Applications Research Grade Biosimilar
Host species Chimeric
Isotype IgG1-kappa
Expression system Mammalian Cells
Clonality Monoclonal
Target Ganglioside GD2
Endotoxin level Please contact the lab for this information.
Purity >95% purity as determined by SDS-PAGE.
Purification Protein A/G, purified from cell culture supernatant.
Accession CAS: 65988-71-8
Form Liquid
Storage buffer 0.01M PBS,pH7.4.
Stability and Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C.
Alternate Names 14.18 mAb, 14.18-IL-2, EMD273063, EMD-273063, Hu14.18-IL-2, Hu14.18-IL2, anti-GD2 fused to IL2, hu14.18-IL2, hu14.18-Interleukin-2 fusion protein, CAS: 2131168-99-3
Background Lorukafusp alfa (14.18 mAb; hu14.18-IL2) is an immunocytokine consisting of the humanized 14.18 anti-GD2 mAb linked to IL210. Lorukafusp alfa has activity mediated by activation of antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity via the binding of hu14.18-IL2 to GD2 on the tumor cell surface, followed by binding to Fc receptors on effector cells along with activation of NK and T cells via IL2 receptor binding. Lorukafusp alfa has anti-tumor activity.
Note For research use only. Not for use in clinical or therapeutic applications.